BeiGene upgraded by BofA Securities with a new price target
$ONC
Biotechnology: Pharmaceutical Preparations
Health Care
BofA Securities upgraded BeiGene from Neutral to Buy and set a new price target of $320.00 from $207.00 previously
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 4/7/2025 | $312.00 | Outperform | RBC Capital Mkts |
| 3/3/2025 | $207.00 → $320.00 | Neutral → Buy | BofA Securities |